Cannabinoids and Mental Health, Part 2 : The Search for Clinical Applications
Copyright 2019, SLACK Incorporated..
Patients with psychiatric conditions are increasingly using cannabinoids, particularly cannabidiol (CBD), to treat their own symptoms. After reviewing the mechanism of action of CBD, the current article examines the existing evidence for CBD in the treatment of schizophrenia, anxiety, autism, posttraumatic stress disorder, and insomnia, and discusses the challenges in translating these studies, often using very high doses of CBD, into clinical practice. Until additional, well-designed studies that examine the more common practice of lower doses of CBD are performed, a harm-reduction, patient-centered, empiric approach is encouraged to optimize symptom reduction while at the same time avoiding the known risks of cannabis. [Journal of Psychosocial Nursing and Mental Health Services, 57(10), 7-11.].
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2019 |
---|---|
Erschienen: |
2019 |
Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
---|---|
Enthalten in: |
Journal of psychosocial nursing and mental health services - 57(2019), 10 vom: 01. Okt., Seite 7-11 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Penn, Andrew [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 09.03.2020 Date Revised 09.03.2020 published: Print Citation Status MEDLINE |
---|
doi: |
10.3928/02793695-20190919-02 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM301810982 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM301810982 | ||
003 | DE-627 | ||
005 | 20231225105412.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2019 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3928/02793695-20190919-02 |2 doi | |
028 | 5 | 2 | |a pubmed24n1006.xml |
035 | |a (DE-627)NLM301810982 | ||
035 | |a (NLM)31573659 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Penn, Andrew |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cannabinoids and Mental Health, Part 2 |b The Search for Clinical Applications |
264 | 1 | |c 2019 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.03.2020 | ||
500 | |a Date Revised 09.03.2020 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright 2019, SLACK Incorporated. | ||
520 | |a Patients with psychiatric conditions are increasingly using cannabinoids, particularly cannabidiol (CBD), to treat their own symptoms. After reviewing the mechanism of action of CBD, the current article examines the existing evidence for CBD in the treatment of schizophrenia, anxiety, autism, posttraumatic stress disorder, and insomnia, and discusses the challenges in translating these studies, often using very high doses of CBD, into clinical practice. Until additional, well-designed studies that examine the more common practice of lower doses of CBD are performed, a harm-reduction, patient-centered, empiric approach is encouraged to optimize symptom reduction while at the same time avoiding the known risks of cannabis. [Journal of Psychosocial Nursing and Mental Health Services, 57(10), 7-11.] | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Cannabidiol |2 NLM | |
650 | 7 | |a 19GBJ60SN5 |2 NLM | |
773 | 0 | 8 | |i Enthalten in |t Journal of psychosocial nursing and mental health services |d 1983 |g 57(2019), 10 vom: 01. Okt., Seite 7-11 |w (DE-627)NLM012985686 |x 0279-3695 |7 nnns |
773 | 1 | 8 | |g volume:57 |g year:2019 |g number:10 |g day:01 |g month:10 |g pages:7-11 |
856 | 4 | 0 | |u http://dx.doi.org/10.3928/02793695-20190919-02 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 57 |j 2019 |e 10 |b 01 |c 10 |h 7-11 |